General information/press room, American Thyroid Association (2025) Assessment of thyroid carcinogenic risk and safety profile of GLP1-RA semaglutide (Ozempic) therapy for diabetes mellitus and obesity: A systematic literature review, International Journal of Molecular Sciences (2024) Diabetes mellitus and thyroid cancers: risky correlation, underlying mechanisms and clinical prevention, Diabetes, Metabolic Syndrome, and Obesity (2024) Hyperthyroidism, Cleveland Clinic (2024) Hyperthyroidism, MedLinePlus (2024) Hypothyroidism, Cleveland Clinic (2024) Implications of GLP-1 receptor agonist on thyroid function: A literature review of its effects on thyroid volume, risk of cancer, functionality and TSH levels, Biomolecules (2024) Safety of semaglutide, Frontiers in Endocrinology (2021) Semaglutide injection, MedLinePlus (2025) Semaglutide reprograms macrophages via the GLP-1R/PPARG/ACSL1 pathway to suppress papillary thyroid carcinoma growth, The Journal of Clinical Endocrinology and Metabolism (2025) Suppressed thyroid stimulating hormone levels after initiation of a subcutaneous glucagon-like peptide-1 receptor agonist in a post-thyroidectomy patient managed with levothyroxine case report, Journal of the American Pharmacists Association (2024) Use of GLP-1 receptor agonists and occurrence of thyroid disorders: A meta-analysis of randomized controlled trials, Frontiers in Endocrinology (2022) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
However, its essential to consult with a trusted, board-certified plastic surgeon so you can make the best decision for your body and lifestyle
doi: 10.1016/j.msard.2024.106229
I want to share one story that illustrates what can happen when we focus on root causes not just symptom suppression
Vasopressin induces apoptosis but does not enhance the antiproliferative effect of dynamin 2 or PI3K/Akt inhibition in luminal A breast cancer cells
NICE and British Association of Dermatologists guidelines do not include GLP-1 agonists for psoriasis management
